세계의 ADHD 및 자폐증 디지털 치료제 시장 : 예측 - 제품별, 연령층별, 치료 포커스별, 전달 모드별, 최종 사용자별, 지역별 분석(-2032년)

According to Stratistics MRC, the Global Digital Therapeutics for ADHD & Autism Market is accounted for $1.3 billion in 2025 and is expected to reach $5.4 billion by 2032 growing at a CAGR of 21.7% during the forecast period. Digital Therapeutics (DTx) for ADHD and Autism are evidence-based, software-driven interventions designed to prevent, manage, or treat symptoms of these neurodevelopmental disorders. Utilizing digital platforms such as apps, video games, and interactive programs, DTx aim to improve attention, cognitive flexibility, emotional regulation, and social skills. They complement traditional therapies, providing personalized, engaging, and scalable treatment options. Clinically validated and often prescribed by healthcare professionals, these digital solutions offer continuous monitoring, adaptive learning, and behavioral feedback, enhancing patient outcomes while reducing reliance on medication and supporting long-term developmental progress.

Market Dynamics:

Driver:

Technological advancements in digital health

Digital therapeutics are enabling personalized interventions, real-time progress tracking, and remote engagement. Integration with behavioral analytics, speech therapy, and cognitive training is enhancing treatment outcomes. Schools, clinics, and caregivers are adopting tech-enabled tools to support neurodiverse individuals. Public and private investments in digital health infrastructure are reinforcing adoption. These dynamics are positioning digital innovation as a key driver of the ADHD & autism therapeutics market, thereby boosting overall market growth.

Restraint:

Regulatory and reimbursement challenges

Developers face hurdles in securing approvals, validating clinical efficacy, and navigating data privacy laws. Payers remain cautious about coverage for non-traditional interventions, affecting accessibility. Regional disparities in digital health policy and licensing are complicating deployment. Lack of standardized outcome metrics is hindering scalability and trust. These factors are tempering market expansion despite strong technological momentum.

Opportunity:

Growing investment and market potential

Venture capital, government grants, and strategic partnerships are accelerating product development and platform integration. Educational institutions, employers, and healthcare providers are investing in scalable, evidence-based digital solutions. Demand for non-invasive, personalized, and accessible therapies is reinforcing innovation. Public health initiatives and inclusive education mandates are supporting adoption. These developments are creating favorable conditions for market growth, thereby accelerating uptake of digital therapeutics.

Threat:

Cost and accessibility issues

Digital literacy gaps and infrastructure constraints are affecting user engagement and retention. Providers must invest in localization, affordability, and hybrid delivery models to overcome barriers. Disparities in internet access and device availability are reducing reach in rural and underserved regions. Limited integration with traditional care pathways is slowing clinical adoption. These limitations are introducing systemic risk and constraining full-scale market development.

Covid-19 Impact:

The Covid-19 pandemic disrupted the Digital Therapeutics for ADHD & Autism market, causing temporary delays in clinical validation, platform deployment, and in-person assessments. Educational institutions, therapy centers, and diagnostic facilities experienced reduced capacity, impacting continuity of care. However, the increased focus on mental health, remote engagement, and digital-first interventions partially offset the slowdown. Post-pandemic recovery is driven by growing demand for accessible, tech-enabled, and personalized neurodevelopmental support solutions, along with innovations in virtual therapy platforms and home-based interventions across user segments.

The software applications segment is expected to be the largest during the forecast period

The software applications segment is expected to account for the largest market share during the forecast period owing to its scalability, cost-efficiency, and ease of integration across devices and platforms. Mobile apps, web-based tools, and AI-driven interfaces are enabling real-time monitoring, adaptive learning, and behavioural reinforcement. Providers are optimizing algorithms for age-specific, culturally adaptive, and clinically validated interventions. Demand remains strong across healthcare, education, and homecare domains. Regulatory support for digital health and data interoperability is reinforcing adoption. This segment continues to anchor the digital therapeutics market, thereby boosting overall market growth.

The educational institutions segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the educational institutions segment is predicted to witness the highest growth rate driven by demand for inclusive, tech-enabled, and scalable support for neurodiverse students. Schools are adopting digital therapeutics to enhance learning outcomes, reduce behavioural disruptions, and support individualized education plans. Integration with classroom tools, teacher dashboards, and student progress trackers is improving engagement and accountability. Public funding and policy mandates for special education are accelerating deployment. Demand for evidence-based, accessible solutions is reinforcing momentum, thereby accelerating market expansion.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced digital health ecosystem, strong reimbursement infrastructure, and high awareness of neurodevelopmental conditions. The U.S. and Canada are leading in clinical validation, platform deployment, and regulatory approvals. Public initiatives in mental health, inclusive education, and digital therapeutics are reinforcing demand. Regional startups and academic institutions are driving innovation in AI, UX design, and therapeutic content. Insurance coverage and school-based programs are supporting widespread adoption.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR driven by rising paediatric population, expanding digital infrastructure, and government investment in neurodevelopmental care. Countries like China, India, Japan, and South Korea are scaling school-based screening, mobile health platforms, and inclusive education programs. Public-private partnerships and mobile-first strategies are improving access in urban and semi-urban areas. Demand for affordable, culturally adaptive, and multilingual tools is reinforcing innovation.

Key players in the market

Some of the key players in Digital Therapeutics for ADHD & Autism Market include Cognoa Inc., Akili, Inc., Pear Therapeutics, Inc., CogniFit Inc., BrainWare Learning Company, Neurocog Trials, Inc., Headspace Health, Mightier, Elemy Health, Floreo Inc., NeuroFlow Inc., Limbix Health, Inc., Total Brain, Koa Health and Bold Health.

Key Developments:

In July 2025, Cognoa expanded partnerships with Highmark Health and HTAhealth, enabling broader access to its AI-powered autism diagnostic, Canvas Dx, for self-insured employers and commercial health plans. These collaborations support scalable deployment and reimbursement of digital diagnostics across pediatric populations.

In March 2024, Akili entered a strategic partnership with Shionogi & Co. Ltd. to commercialize its ADHD and autism digital therapeutics in Japan and Taiwan, with milestone payments up to $125M. Shionogi will lead clinical development and marketing, while Akili manages global platform operations and data compliance.

Products Covered:

• Software Applications
• Devices (Wearables)
• Platforms (Telehealth Solutions)

Age Groups Covered:

• Children
• Adolescents
• Adults

Therapeutic Focuses Covered:

• Cognitive Behavioural Therapy (CBT)
• Social Skills Training
• Attention Training
• Sleep Management
• Anxiety and Stress Management

Delivery Modes Covered:

• Mobile Applications
• Web-Based Platforms
• Virtual Reality (VR)
• Augmented Reality (AR)

End Users Covered:

• Individuals
• Healthcare Providers
• Educational Institutions
• Caregivers and Families
• Employers & Workplace
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Digital Therapeutics for ADHD & Autism Market, By Product

• 5.1 Introduction
• 5.2 Software Applications
• 5.3 Devices (Wearables)
• 5.4 Platforms (Telehealth Solutions)

6 Global Digital Therapeutics for ADHD & Autism Market, By Age Group

• 6.1 Introduction
• 6.2 Children
• 6.3 Adolescents
• 6.4 Adults

7 Global Digital Therapeutics for ADHD & Autism Market, By Therapeutic Focus

• 7.1 Introduction
• 7.2 Cognitive Behavioral Therapy (CBT)
• 7.3 Social Skills Training
• 7.4 Attention Training
• 7.5 Sleep Management
• 7.6 Anxiety and Stress Management

8 Global Digital Therapeutics for ADHD & Autism Market, By Delivery Mode

• 8.1 Introduction
• 8.2 Mobile Applications
• 8.3 Web-Based Platforms
• 8.4 Virtual Reality (VR)
• 8.5 Augmented Reality (AR)

9 Global Digital Therapeutics for ADHD & Autism Market, By End User

• 9.1 Introduction
• 9.2 Individuals
• 9.3 Healthcare Providers
• 9.4 Educational Institutions
• 9.5 Caregivers and Families
• 9.6 Employers & Workplace
• 9.7 Other End Users

10 Global Digital Therapeutics for ADHD & Autism Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Cognoa Inc.
• 12.2 Akili, Inc.
• 12.3 Pear Therapeutics, Inc.
• 12.4 CogniFit Inc.
• 12.5 BrainWare Learning Company
• 12.6 Neurocog Trials, Inc.
• 12.7 Headspace Health
• 12.8 Mightier
• 12.9 Elemy Health
• 12.10 Floreo Inc.
• 12.11 NeuroFlow Inc.
• 12.12 Limbix Health, Inc.
• 12.13 Total Brain
• 12.14 Koa Health
• 12.15 Bold Health